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Allelic variants of streptokinase from Streptococcus pyogenes display functional
differences in plasminogen activation.
Abstract
A common mammalian defence mechanism employed to prevent systemic dissemination of invasive
bacteria involves occlusion of local microvasculature and encapsulation of bacteria within fibrin
networks. Acquisition of plasmin activity at the bacterial cell surface circumvents this defence
mechanism allowing invasive disease initiation. To facilitate this process, S. pyogenes secrete
streptokinase, a plasminogen activating protein. Streptokinase polymorphism exhibited by S. pyogenes
isolates is well characterised. However, the functional differences displayed by these variants and the
biological significance of this variation has not been elucidated. Phylogenetic analysis of ska sequences
from 28 S. pyogenes isolates revealed two main sequence clusters (clusters 1 and 2). All strains secreted
streptokinase as determined by western blotting and were capable of acquiring cell-surface plasmin
activity after incubation in human plasma. Whereas culture supernatants from strains containing cluster 1
ska alleles also displayed soluble plasminogen activation activity, supernatants from strains containing
cluster 2 ska alleles did not. Furthermore, plasminogen activation activity in culture supernatants from
strains containing cluster 2 ska alleles could only be detected when plasminogen was pre-bound with
fibrinogen. This study indicates that variant streptokinase proteins secreted by S. pyogenes isolates
display differing plasminogen activation characteristics and may therefore play distinct roles in disease
pathogenesis.
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Abstract
A common mammalian defence mechanism employed to prevent systemic dissemination of
invasive bacteria involves occlusion of local microvasculature and encapsulation of bacteria
within fibrin networks. Acquisition of plasmin activity at the bacterial cell surface
circumvents this defence mechanism allowing invasive disease initiation. To facilitate this
process, S. pyogenes secrete streptokinase, a plasminogen activating protein. Streptokinase
polymorphism exhibited by S. pyogenes isolates is well characterised. However, the
functional differences displayed by these variants and the biological significance of this
variation has not been elucidated. Phylogenetic analysis of ska sequences from 28 S. pyogenes
isolates revealed two main sequence clusters (clusters 1 and 2). All strains secreted
streptokinase as determined by western blotting and were capable of acquiring cell-surface
plasmin activity after incubation in human plasma. Whereas culture supernatants from strains
containing cluster 1 ska alleles also displayed soluble plasminogen activation activity,
supernatants from strains containing cluster 2 ska alleles did not. Furthermore, plasminogen
activation activity in culture supernatants from strains containing cluster 2 ska alleles could
only be detected when plasminogen was pre-bound with fibrinogen. This study indicates that
variant streptokinase proteins secreted by S. pyogenes isolates display differing plasminogen
activation characteristics and may therefore play distinct roles in disease pathogenesis.

Key words; bacterial pathogenesis, virulence, invasive disease.
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Introduction
Group A streptococcus (Streptococcus pyogenes; GAS) is a common bacterial pathogen
whose virulence has been honed through the process of evolution with its singular human
host. GAS employ numerous pathogenic mechanisms that interact specifically with human
proteins which enable evasion of host defences and promote bacterial colonisation,
proliferation and dissemination. As an early mammalian defence mechanism, invading
bacterial pathogens such as GAS are confined at sites of infection through the deposition of
fibrin networks, thereby allowing a directed inflammatory immune response to specifically
target this area (1). To circumvent this defence mechanism, GAS subvert components of the
host fibrinolytic system to degrade fibrin and thus spread to other areas of the body (2).

A key component of the fibrinolytic system is plasminogen. Plasminogen is a 92 kDa
glycoprotein found in plasma and extracellular fluids (3). Cleavage of the plasminogen
activation bond (i.e. Arg561-Val562) by the specific host plasminogen activators, urokinase
(uPA) and tissue plasminogen activator (tPA), results in the formation of the serine protease,
plasmin (4). Plasmin has a broad substrate spectrum that includes fibrin clots and the
extracellular matrix (4). GAS secrete streptokinase, a human specific plasminogen activating
protein. Unlike host plasminogen activators, streptokinase lacks any intrinsic enzymatic
activity and activates plasminogen by forming a stable 1:1 stoichiometric complex with either
plasminogen or plasmin (5). Both complexes display the broad-spectrum protease activity of
plasmin but this activity is unique in that it cannot be regulated by the normal plasma
inhibitors (i.e. α2-antiplasmin and α2-macroglobulin) and can also activate other molecules of
plasminogen (6).
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Plasminogen contains several distinct structural domains, consisting of the amino-terminal
peptide, followed by Kringle domains 1–5 (K1-5) and the carboxy-terminal serine protease
domain. K1, K4 and K5 contain lysine-binding motifs that are responsible for binding to
fibrinogen and to plasminogen receptors (7). The circulating, soluble form of plasminogen
(glu-plasminogen) is maintained in a closed form through lysine-dependent interaction/s
between the amino-terminal peptide and K5. Upon binding to mammalian or bacterial
receptors, a conformational change is induced in glu-plasminogen producing an open,
activation-susceptible form (6, 7).

GAS capture and facilitate plasminogen activation to plasmin, conferring cell-bound
proteolytic activity, by several pathways. Plasminogen bound directly to GAS via cell-surface
receptors such as the plasminogen-binding group A streptococcal M-like proteins (PAM) (810), glyceraldehye-3-phosphate dehydrogenase (GAPDH) (11) or streptococcal enolase
(SEN) (12), can be activated by streptokinase:plasminogen/plasmin complexes, or by host
activators such as tissue plasminogen activator (13). Alternatively, plasmin formed in solution
may subsequently bind to GAS cell-surface receptors (14, 15). GAS may also acquire cellsurface plasmin activity by binding a tri-molecular complex of plasminogen, human
fibrinogen and streptokinase (16, 17).

Streptokinase alleles from GAS are polymorphic (18). Previous studies have linked
streptokinase polymorphism with strains associated with acute post-streptococcal
glomerulonephritis (19, 20) and with strains that exhibit skin tissue tropism (21). However,
the functional significance of streptokinase polymorphism has not been elucidated. With the
majority of structural and functional studies on streptokinase having been performed using the
therapeutic streptokinase from group C streptococcus, the phenotypic differences displayed by
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GAS streptokinase proteins has yet to be explored. This report investigates streptokinase
polymorphism in a number of clinical GAS isolates and demonstrates that variant
streptokinase proteins display differing plasminogen activation capacities.

Materials and Methods
GAS isolates and culture
The 28 GAS isolates from the Northern Territory of Australia used in this study were
collected from patients between 1990 and 1998 and their clinical source, emm type, pam
genotype and plasminogen binding characteristics have been described in detail (17). This
strain set was selected, as the region suffers endemic GAS infections, and the strains
examined were epidemiologically diverse. Pam-positive isolates were defined as those
positive for pam by Southern hybridisation and containing pam encoding A1 and A2 repeat
regions with greater than 50% amino acid sequence homology to that of the prototype PAM
sequence (8). The invasive GAS isolate 5448 (M type 1), the North American emm53
impetigo isolate ALAB49 and its isogenic streptokinase deletion mutant have been described
previously (22-26). GAS were cultured on defibrinated horse blood agar plates (Biomerieux,
Sydney, NSW, Australia) or in Todd Hewitt broth (BD, Sydney, NSW, Australia)
supplemented with 1% (w/v) yeast extract (Oxoid, Adelaide, SA, AUstralia; THY) at 37°C as
stationary cultures.

Streptokinase expression
For analysis of streptokinase expression, aliquots of overnight GAS cultures were washed
twice by centrifugation and subsequent resuspension with an equal volumes of fresh THY
before being used to inoculate new cultures. When GAS cultures had reached mid-log phase
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(A600 = 0.6), supernatants were harvested by centrifugation, filtered using a 0.2 µm PVDF
syringe filter (Millipore, Sydney, NSW, Australia) and stored at -70°C until analysis.

Thawed GAS culture supernatants were then concentrated 18 fold by 10% trichloroacetic acid
precipitation prior to SDS-PAGE and Western transfer to PVDF membrane (Millipore). For
detection of streptokinase, the membranes were immunoblotted using rabbit immune serum
raised against commercial group C streptokinase (Sigma-Aldrich, Sydney, NSW, Australia)
as described previously (27).

Streptokinase activity
An indirect plasminogen activation assay was used to measure streptokinase activity in GAS
culture supernatants using the plasmin amidolytic substrate Spectrozyme® PL (American
Diagnostica, Stamford, CT, USA), as previously described (28). Briefly, supernatants were
defrosted on ice and a 20 μl aliquot incubated at 37°C with 100 μl 50 mM Tris, pH 7.5,
containing 20 μg/ml glu-plasminogen (Haematologic Technologies, Essex Junction, Vermont
USA) for 15 min. Spectrozyme® PL (20 μl of 2.5 mM) was added and absorbance at 405 nm
was measured every 3 min for 60 min. Absorbance was plotted against time and activity rates
were determined from the linear portion of the curve. The amount of streptokinase activity in
each bacterial culture supernatant was converted to units/ml using a standard curve of group C
streptokinase (Sigma-Aldrich) serially diluted in THY medium using Softmax® Pro software.
All reactions were performed in duplicate in the presence and absence of plasminogen to
confirm that proteolytic activity of supernatants was attributable to plasminogen activation.
Inter-assay variation was corrected for using an internal positive control sample (250 units/ml
of purified group C streptokinase; Sigma-Aldrich) in each assay. In assays examining the
effects of plasminogen binding ligands on streptokinase mediated plasminogen activation,
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human fibrinogen (Sigma), recombinant streptococcal enolase (SEN) (29) or recombinant
PAM (30) were mixed in 1:1 stoichiometric ratios with plasminogen and pre-incubated at
37°C for 15 min prior to the addition of bacterial culture supernatants.

Cell surface plasmin activity
Plasmin acquisition by S. pyogenes isolates after incubation in human plasma was determined
essentially as described previously (27). Frozen plasma was purchased from the Red Cross
Blood Bank (Sydney, NSW, Australia), defrosted on ice and pooled. Aliquots of pooled
plasma were depleted of plasminogen by incubation at 4°C on ice with excess lysinesepharose® 4B (Amersham Biosciences, Sydney, NSW, Australia) for 1–2 h with gentle
agitation. GAS were cultured overnight, washed once in PBS, pH 7.4, and resuspended to
A600 = 0.7. Aliquots of this suspension were pelleted by centrifugation (1500 x g for 10 min)
and resuspended in an equal volume of 100% human plasma or plasminogen-depleted plasma
at 37°C. GAS were incubated in plasma for 3 h at 37°C, pelleted by centrifugation and
washed twice with 1 volume of ice-cold 0.01 M EDTA, 0.1% gelatin in PBS, pH 7.4. GAS
were resuspended in 0.1% gelatin in PBS, pH 7.4 to A600 = 0.75. Aliquots (100 µl) of this
suspension were incubated in triplicate in the presence and absence of 20 µl Spectrozyme®
PL (2.5 mM) at 37°C for 60 min in a 96-well plate. The reaction was quenched with 80 µl of
1.75 M acetic acid, the plates centrifuged and A405 of supernatants determined.

Plasmin activity was determined as the difference between A405 in the presence and absence
of substrate. Isolate NS931 was included as an internal control in every experiment. Each
isolate was assayed in at least 3 independent experiments. Plasmin equivalents and the linear
range of the assay (A405 = 0 – 0.6) were determined using a standard curve of purified plasmin
(Roche Diagnostics, Sydney, NSW, Australia).
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Streptokinase genotype
Chromosomal DNA was extracted from GAS strains using a commercially available system
(DNeasy Kit, Qiagen, Melbourne, Vic, Australia). The variable region of the streptokinase
gene was PCR-amplified using previously described primers (31), sequenced using the
BigDye Terminator cycle sequencing kit and analysed using ABI Prism Autoassembler
software (Applied Biosystems, Melbourne, Vic, Australia). A phylogenetic tree was
constructed for the 423 bp nucleotide sequence encoding the variable β-domain of the
streptokinase protein of the 29 NT isolates using MEGA (32) as previously described (21).
The Genbank accession numbers for the 29 partial ska sequences are EU352612 to
EU352641.

Statistical analyses
Differences of enzyme activities between isolates were determined using unpaired, two tailed
Student’s t-test with 95% confidence intervals. The effect of pre-binding ligands to
plasminogen on streptokinase activation was analysed using a one way ANOVA and a
Newman-Keuls multi-comparison post test. All statistical analyses were carried out using
GraphPad Prism (GraphPad Software Inc., San Diego, CA, USA).

Results
Phylogenetic analysis of streptokinase β-domain gene sequences
The relatedness of streptokinase alleles from 5448, ALAB49 and 28 NT GAS isolates were
investigated by phylogenetic analysis of nucleotide sequences encoding the highly variable βdomain of streptokinase (Figure 1). The β-domain sequences were found to cluster into two
major groups (clusters 1 and 2) with evidence of several smaller subclusters present. This
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phylogeny is similar to that seen in previous studies (21). The ska alleles of all pam-negative
isolates fell within cluster 1, with the exceptions of the two emm1 isolates NS696 and 5448
which fell within a smaller subcluster of cluster 2 alleles termed cluster 2a. The majority of
pam-positive isolates (12/13) possessed a cluster 2 allele that was termed cluster 2b. A
notable exception was the pam-positive isolate NS53, which possessed a cluster 1 ska allele.
This association between cluster 2b ska alleles and pam genotype has been previously
observed (21).

Activity and expression of streptokinase allelic variants
Streptokinase activity was determined in supernatants collected from cultures at mid-log
phase for the 31 GAS isolates. The results demonstrate a striking difference in soluble
plasminogen activation capacities displayed by the different streptokinase variants produced
by each isolate. For all strains harbouring a cluster 1 ska allele, there were high levels of
streptokinase activity present in culture supernatants (Figure 2A). These ranged from 9 to 132
units/ml. For strains harbouring a cluster 2 ska allele, no streptokinase activity was detected in
the culture supernatants (Figure 2A). The pam-positive strain, NS53, which contains a cluster
1 ska allele produced measurable streptokinase activity (33 units/ml) in culture supernatants
(Figure 2A).

We next investigated whether the lack of soluble streptokinase activity seen in culture
supernatants from strains containing a cluster 2 ska allele was due to a lack of streptokinase
protein in culture supernatants. Western immunoblotting experiments using anti-SpeB
polyclonal sera demonstrated that the cysteine protease SpeB, which is known to degrade
streptokinase (33) was not present in supernatants harvested at this phase of growth (data not
shown). This was corroborated by Western-immunoblotting performed using anti-
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streptokinase polyclonal sera as it detected an immunoreactive band ranging from
approximately 46 to 49 kDa in culture supernatants for all GAS isolates, including those
harbouring a cluster 2 ska allele (Figure 2B). This corresponds to the approximate size of
streptokinase (28). The ALAB49Δska mutant strain lacked this 46 to 49 kDa immunoreactive
band, instead producing a 27 kDa band that is consistent with the expected size of the
truncated streptokinase protein produced by this strain (25). These results clearly show the
lack of soluble streptokinase activity in culture supernatants from isolates with a cluster 2 ska
allele was not attributable to a lack of streptokinase protein being present in these samples.

Acquisition of cell-surface plasmin by GAS isolates in plasma
To determine whether the secreted streptokinase protein encoded by cluster 2 ska alleles was
inactive, an indirect assay measuring the acquisition of cell-surface bound plasmin after
incubation in human plasma was performed for all isolates (Figure 3). Despite the apparent
lack of streptokinase activity in solution, isolates containing a cluster 2 ska allele acquired
significantly higher levels of plasmin activity at the cell surface compared to the isolates
containing a cluster 1 ska allele (Figure 3; p = 0.0018). As might be expected, the isogenic
streptokinase-negative mutant ALAB49Δska acquired significantly less cell-surface plasmin
activity than wild-type ALAB49 (Figure 3; p = 0.019). As secreted cluster 2 type
streptokinase appears to contribute to cell-surface plasmin acquisition, these observations
suggest that this type of streptokinase is active but only in the presence of cell surface
receptors and/or human plasma.

Effects of plasminogen binding receptors on plasminogen activation by streptokinase
Fibrinogen can contribute to the acquisition of cell surface plasmin activity by binding
streptokinase-plasminogen complexes to M-proteins located on the bacterial cell surface (16).
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The effect of pre-binding plasminogen to fibrinogen on plasminogen activation by group A
streptococcal streptokinase variants was thus examined (Figure 4). Fibrinogen significantly
increased the streptokinase activity detected in GAS culture supernatants from isolates
harbouring cluster 1 ska alleles when compared to activities detected in the absence of
fibrinogen (Figure 4A; p<0.001). Importantly, streptokinase activity was also detected in GAS
culture supernatants from isolates harbouring the cluster 2 ska alleles when plasminogen was
pre-bound with fibrinogen (Figure 4A).

The binding of glu-plasminogen to mammalian or bacterial receptors induces a
conformational change that can affect the activation of this zymogen (6, 7). When
plasminogen was pre-bound to PAM, a significant increase in streptokinase activity in GAS
culture supernatants from isolates harbouring cluster 1 and cluster 2a ska alleles was observed
when compared to activities detected in the absence of PAM (Figure 4B; p<0.01). However,
this enhanced streptokinase activity is not biologically relevant as the majority of cluster 1 ska
allele GAS strains do not express PAM. GAS culture supernatants from pam-positive isolates
harbouring a cluster 2b ska allele did not produce detectable streptokinase activity when
plasminogen was pre-bound to PAM (Figure 2B). When plasminogen was pre-bound to SEN,
streptokinase activity in all GAS culture supernatants was similar to levels detected in the
absence of SEN (Figure 4C; p>0.05). When plasminogen was pre-bound to a combination of
fibrinogen and PAM or fibrinogen and SEN, streptokinase activity was increased to levels
similar to those seen for fibrinogen alone suggesting that the presence of PAM or SEN does
not confer an additional benefit (Figure 4D and E). For all reaction conditions, ALAB49Δska
did not exhibit streptokinase activity in culture supernatants (Figure 4). These data
demonstrate that, for cluster 2 ska alleles, the presence of fibrinogen is a prerequisite for the
cluster 2 streptokinase-plasminogen complex to gain functional activity.
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Discussion
Activating plasminogen and acquiring plasmin activity to the bacterial cell surface has been
recognised as a pathogenic mechanism for a variety of bacterial species that can cause
invasive infections (34, 35). A long standing question in group A streptococcal research has
been the correlation of high level cell surface plasminogen binding capacity with the absence
of detectable streptokinase activity (2, 28). In this report, we demonstrate for the first time
that allelic variants of streptokinase produced by different GAS isolates display unique
plasminogen activation properties which confer on all GAS isolates the potential to harness
plasmin activity onto the bacterial cell surface.

Plasminogen receptors interact with different regions of the plasminogen protein. The GAS
plasminogen-binding M protein, PAM, binds to plasminogen via interaction with K2 (36),
whereas fibrinogen and the GAS plasminogen receptors SEN and GAPDH bind via lysine
dependant interactions with K1, K4 and K5 (7). Streptokinase encoded by cluster 2b ska
alleles failed to produce any soluble plasminogen activation activity in the absence of
fibrinogen. Pre-binding of the plasminogen receptors PAM or SEN to plasminogen did not
enhance plasminogen activation by cluster 2b allelic variants of streptokinase. This is
consistent with previous studies that have noted specific isolates of S. pyogenes fail to activate
plasminogen (28). All the GAS isolates used in this current study expressed and secreted
streptokinase into culture supernatants indicating that the lack of plasminogen activation
activity was not due to lack of ska expression. Streptokinase encoded by cluster 2b ska alleles
was able to activate plasminogen when pre-bound to fibrinogen or to cells pre-incubated in
human plasma. Cluster 2b streptokinase expression by the PAM-positive strain ALAB49, was
required for cell-surface plasmin acquisition during incubation in human plasma as deletion of
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the ska gene in ALAB49Δska abolished surface plasmin acquisition. Streptokinase encoded
by cluster 2a ska alleles also readily activated plasminogen to produce plasmin activity in the
presence of fibrinogen. Taken together, these data suggest cluster 2 streptokinase requires the
formation of a tri-molecular complex with plasminogen and fibrinogen in order to display
plasminogen activating capability.

Streptokinase encoded by cluster 1 ska alleles readily activated soluble plasminogen to
produce plasmin activity. The addition of fibrinogen to cluster 1 ska supernatants resulted in
significantly higher levels of streptokinase activity (Figure 4). Similarly, activation of gluplasminogen by group C streptokinase can be enhanced when plasminogen is pre-bound with
fibrinogen (37). Although SEN has been shown to bind to plasminogen (38), this interaction
did not affect plasminogen activation mediated by any of the streptokinase variants examined
in this study.

Kalia and Bessen (21) demonstrated a strong linkage disequilibrium between skin-tropic GAS
strains, cluster 2b ska alleles and PAM suggesting the resultant phenotype may contribute to
increased bacterial fitness during skin infection. In this study 13 of the 14 pam-positive strains
contained a cluster 2b ska allele. Although PAM was shown to have no effect on plasminogen
activation by streptokinase encoded by cluster 2b allele types, we hypothesise that PAM,
rather than playing a direct role in plasminogen activation, has evolved to bind to K2 of
plasminogen, allowing fibrinogen to interact with K4 and K5 in a non-competitive manner.
This allows the plasminogen-fibrinogen-streptokinase tri-molecular complex to bind to the
surface of PAM-positive GAS isolates expressing cluster 2b ska (Figure 5A). Supporting this
hypothesis, Svensson et al. (25) showed that an isogenic pam knockout mutant of ALAB49
failed to acquire and activate plasminogen after incubation in human plasma. Other GAS
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plasminogen binding proteins such as SEN cannot bind this tri-molecular complex as the
plasminogen domains (K 4 and K5) required for interaction with SEN are involved in the
interaction with fibrinogen. This hypothesis accounts for the co-selection of PAM and cluster
2b ska observed by Kalia and Bessen (21). For cluster 2a GAS, the fibrinogen-binding
capacity of M1 protein (39-41) allows attachment of the tri-molecular complex to the bacterial
surface (Figure 5B). In contrast, cluster 1 GAS produces a streptokinase molecule that does
not require the participation of fibrinogen to activate plasminogen. We hypothesise that
anchoring of the cluster 1 streptokinase-plasminogen complex to the GAS cell surface can
occur via the interaction of K4 and K5 with SEN or other plasminogen receptors, or
alternatively via the interaction of the cluster 1 streptokinase-plasminogen complex with
fibrinogen bound to GAS fibrinogen receptors (Figure 5C).

Our results show that allelic variants of streptokinase produced by different GAS strains
exhibit differing plasminogen activation capacities. This suggests that variation within the β
domain of these proteins may be responsible for the observed differences in plasminogen
activation activities. Lizano and Johnston (42) have suggested that sequence polymorphism in
the β-domain has little affect on plasminogen activation. The recombinant streptokinase
produced from SF13013 (containing a cluster 2a ska allele) in that study displayed soluble
plasminogen activation activity. In our study, streptokinase produced by two serotype M1
isolates containing cluster 2a alleles displayed no soluble plasminogen activation activity.
This indicates that sequence differences outside the β-domain region may also contribute to
the variable plasminogen activation activities observed for streptokinase variants produced by
GAS.
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In this study, we demonstrate that activation of plasminogen by cluster 2 type streptokinase
requires the presence of fibrinogen and the formation of a tri-molecular complex between
streptokinase, plasminogen and fibrinogen. This requirement underpins the previously
observed linkage disequilibrium between PAM and cluster 2b alleles (21) as PAM is critical
for harnessing plasmin activity to the bacterial cell surface via binding of the tri-molecular
complex. The sequence diversity of streptokinase displayed by GAS may be the result of
selection pressures acting on ska during the infection process, thereby producing streptokinase
proteins that are better adapted to interact with the human fibrinolytic system while avoiding a
functional immune system. Therefore, understanding the molecular basis for the phenotypic
variations observed in this study could assist the rational design of second generation
thrombolytic therapeutics (43) with improved efficacy and safety.
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Figure legends
Figure 1. Phylogenetic tree for a 423 bp variable region encoding the β-domain of
streptokinase for the 31 isolates examined in this study. The DNA sequence of the ska allele
from ALAB49 (AY234134) was obtained from a previous study (21). Bootstrap values of ≥
90% (500 replicates) are indicated and the scale bar indicates 0.05 substitution per site. PAMpositive GAS isolates are in italics. The Genbank accession numbers for the 29 partial ska
sequences are EU352612 to EU352641.

Figure 2. Solution phase streptokinase activity and expression of 31 clinical isolates of GAS.
(A) Streptokinase activity in GAS culture supernatants at mid-log phase (A600 = 0.6)
measured by an indirect assay of plasmin activity in the presence of human plasminogen
using the plasmin-specific chromogenic substrate Spectrozyme® PL. Results are presented as
the mean of streptokinase activity from duplicate assays, expressed as units/ml using a
standard curve of group C streptokinase and corrected for an internal positive control sample
in each assay. Error bars represent the range for each point. (B) Western blot of mid-log phase
GAS culture supernatants using rabbit immune serum raised against group C streptokinase.
GAS isolates containing a cluster 1 ska allele are indicated with a solid horizontal bar while
isolates containing a cluster 2 ska allele are indicated with a dashed horizontal bar. GAS
isolates containing a sub-cluster 2a ska allele are underlined. PAM-positive GAS isolates are
in italics.

Figure 3. Cell-surface plasmin activity of GAS isolates. Cell surface plasmin activity of 32
clinical isolates of GAS following incubation in human plasma (filled bars) or plasminogendepleted plasma (unfilled bars) determined by cleavage of Spectrozyme® PL. Data represent
mean ± SEM of triplicate cultures of GAS, expressed as A405 of cleaved substrate in solution.
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Overall, strains containing cluster 2 ska alleles acquire more cell-surface plasmin activity
compared to Strains containing cluster 1 ska alleles (p = 0.0018). GAS isolates containing a
cluster 1 ska allele are indicated with a solid horizontal bar while isolates containing a cluster
2 ska allele are indicated with a dashed horizontal bar. GAS isolates containing a sub-cluster
2a ska allele are underlined. PAM-positive GAS isolates are in italics.

Figure 4. Streptokinase activity in GAS culture supernatants at mid-log phase (A600 = 0.6)
measured by an indirect assay of plasmin activity in the presence of human plasminogen prebound with fibrinogen (A), PAM (B), SEN (C), fibrinogen and PAM (D) or fibrinogen and
SEN (E). Results are presented as the mean of streptokinase activity from duplicate assays,
expressed as units/ml using a standard curve of group C streptokinase and corrected for an
internal positive control sample in each assay. Error bars represent the range for each point.
GAS isolates containing a cluster 1 ska allele are indicated with a solid horizontal bar while
isolates containing a cluster 2 ska allele are indicated with a dashed horizontal bar. GAS
isolates containing a sub-cluster 2a ska allele are underlined. PAM-positive GAS isolates are
in italics.

Figure 5. Schematic diagram summarising the hypothesised pathways of cell surface plasmin
acquisition by GAS strains expressing different alleles of streptokinase. (A) Cluster 2b
streptokinase must combine with plasminogen and fibrinogen to form a tri-molecular complex
that exhibits plasmin activity. The tri-molecular complex is bound to the cell surface via the
interaction between PAM and kringle 2 of plasminogen. Other GAS plasminogen binding
proteins such as SEN cannot bind this tri-molecular complex as the domains K 4 and K5
required for interaction are involved in the interaction with fibrinogen. (B) Cluster 2a
streptokinase also must combine with plasminogen and fibrinogen to form a tri-molecular
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complex that exhibits plasmin activity. The tri-molecular complex is bound to the cell surface
via the interaction between fibrinogen binding receptors (FgR) such as M1 protein and
fibrinogen. (C) Cluster 1 type streptokinase will combine with plasminogen to form a
complex with plasmin activity. This complex can be bound directly to the bacterial cell
surface via plasminogen receptors (PLR) or through an interaction with fibrinogen and
fibrinogen receptors.
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